ProShare Advisors LLC Decreases Stake in IQVIA Holdings Inc. (NYSE:IQV)

ProShare Advisors LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.0% in the first quarter, Holdings Channel.com reports. The firm owned 30,043 shares of the medical research company’s stock after selling 628 shares during the period. ProShare Advisors LLC’s holdings in IQVIA were worth $7,598,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. BKM Wealth Management LLC purchased a new position in IQVIA in the 4th quarter valued at approximately $32,000. Dynamic Advisor Solutions LLC lifted its holdings in IQVIA by 15.9% during the 4th quarter. Dynamic Advisor Solutions LLC now owns 1,825 shares of the medical research company’s stock worth $402,000 after purchasing an additional 251 shares in the last quarter. Raymond James Trust N.A. boosted its stake in IQVIA by 5.6% in the 4th quarter. Raymond James Trust N.A. now owns 12,149 shares of the medical research company’s stock worth $2,811,000 after purchasing an additional 647 shares during the period. Cypress Wealth Services LLC purchased a new position in IQVIA during the 4th quarter valued at about $242,000. Finally, Whittier Trust Co. increased its position in shares of IQVIA by 1.2% during the fourth quarter. Whittier Trust Co. now owns 84,749 shares of the medical research company’s stock valued at $19,609,000 after buying an additional 964 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $230.29 on Thursday. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The stock has a market cap of $41.96 billion, a price-to-earnings ratio of 31.46, a PEG ratio of 2.12 and a beta of 1.49. The stock’s 50 day simple moving average is $219.81 and its two-hundred day simple moving average is $228.93. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.11. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. As a group, analysts expect that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Robert W. Baird lowered their target price on shares of IQVIA from $241.00 to $235.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. Evercore ISI dropped their price objective on IQVIA from $250.00 to $230.00 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Monday. The Goldman Sachs Group began coverage on IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective for the company. Finally, Truist Financial reduced their target price on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research note on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $255.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.